Abiraterone and Ensitrelvir: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Abiraterone
Ensitrelvir
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects
Interaction Deep Dive
Concomitant administration of ensitrelvir and CYP3A substrates is contraindicated as it may increase the exposure of CYP3A substrates and may cause adverse effects. In drug interaction studies, concomitant administration of midazolam (CYP3A substrate) (2 mg single oral dose) with ensitrelvir at the clinical dose (375 mg on day 1 and 125 mg on days 2-5) on Day 5 resulted in an approximately 2.80-fold increase in Cmax and a 6.77-fold increase in AUC(0 to inf) of midazolam compared to midazolam administered alone. And, concomitant administration of dexAMETHasone (1 mg single dose) with ensitrelvir (750 mg on day 1 and 250 mg on days 2-5, two fold of the recommended dose) on day 5 and administered alone on day 9 (5 days after the last ensitrelvir dose) and day 14 (10 days after the last ensitrelvir dose) resulted in an approximately 1.47-fold increase in Cmax and a 3.47-fold increase in AUC(0 to inf) of dexAMETHasone on day 5, a 1.24-fold increase in Cmax and 2.38-fold increase in AUC(0 to inf) on day 9, and a 1.17-fold increase in Cmax and a 1.58-fold increase in AUC(0 to inf) on day 14, compared to dexAMETHasone administered alone. Consider initiation of ensitrelvir only after careful evaluation of relevant clinical and pharmacokinetic factors related to the concomitant medication. In addition, consider reinitiation of contraindicated CYP3A substrates based on an assessment of the duration of CYP3A inhibition and patient specific considerations1.
Why it happens (mechanism)
Inhibition of CYP3A-mediated metabolism by ensitrelvir
Literature reports
1 report — tap to read
a) Concomitant administration of midazolam (CYP3A substrate) (2 mg single oral dose) with ensitrelvir at the clinical dose (375 mg on day 1 and 125 mg on days 2-5) on Day 5 resulted in an approximately 2.80-fold increase in Cmax and a 6.77-fold increase in AUC(0 to inf) of midazolam compared to midazolam administered alone. And, concomitant administration of dexAMETHasone (1 mg single dose) with ensitrelvir (750 mg on day 1 and 250 mg on days 2-5, two fold of the recommended dose) on day 5 and administered alone on day 9 (5 days after the last ensitrelvir dose) and day 14 (10 days after the last ensitrelvir dose) resulted in an approximately 1.47-fold increase in Cmax and a 3.47-fold increase in AUC(0 to inf) of dexAMETHasone on day 5, a 1.24-fold increase in Cmax and 2.38-fold increase in AUC(0 to inf) on day 9, and a 1.17-fold increase in Cmax and a 1.58-fold increase in AUC(0 to inf) on day 14, compared to dexAMETHasone administered alone 1.
Common questions
Can I take Abiraterone and Ensitrelvir together?
Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Always confirm with your pharmacist or prescriber before making any change.
How serious is the Abiraterone and Ensitrelvir interaction?
It is rated contraindicated. These should generally not be used together.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Abiraterone or Ensitrelvir need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: XOCOVA® oral tablets, ensitrelvir oral tablets. Shionogi Inc. Florham Park, NJ, 2026. DailyMed
Keep reading about Abiraterone
Keep reading about Ensitrelvir
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist